Intestinal UGTs as potential modifiers of pharmacokinetics and biological responses to drugs and xenobiotics.
about
Identification of diet-derived constituents as potent inhibitors of intestinal glucuronidation.UGT genomic diversity: beyond gene duplication.Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp.Milk Thistle Constituents Inhibit Raloxifene Intestinal Glucuronidation: A Potential Clinically Relevant Natural Product-Drug InteractionMechanisms underlying food-drug interactions: inhibition of intestinal metabolism and transport.In Vitro Metabolism of Montelukast by Cytochrome P450s and UDP-GlucuronosyltransferasesDrug-Drug Interactions Potential of Icariin and Its Intestinal Metabolites via Inhibition of Intestinal UDP-Glucuronosyltransferases.Drug-Drug Interaction Potentials of Tyrosine Kinase Inhibitors via Inhibition of UDP-Glucuronosyltransferases.Quantitative prediction and clinical evaluation of an unexplored herb-drug interaction mechanism in healthy volunteers.Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination.In vitro and in vivo small intestinal metabolism of CYP3A and UGT substrates in preclinical animals species and humans: species differences.Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption.Substrate selectivity of human intestinal UDP-glucuronosyltransferases (UGTs): in silico and in vitro insights.Development of a physiologically based pharmacokinetic/pharmacodynamic model to identify mechanisms contributing to entacapone low bioavailability.Incorporating population variability and susceptible subpopulations into dosimetry for high-throughput toxicity testing.Protein expression of various hepatic uridine 5'-diphosphate glucuronosyltransferase (UGT) enzymes and their inter-correlations: a meta-analysis.Catechol-O-Methyltransferase and UDP-Glucuronosyltransferases in the Metabolism of Baicalein in Different Species.Species differences in intestinal glucuronidation activities between humans, rats, dogs and monkeys.Structural basis for the regulation of β-glucuronidase expression by human gut Enterobacteriaceae.Molecular docking-based design and development of a highly selective probe substrate for UDP-glucuronosyltransferase 1A10.
P2860
Q34185989-C8D7EFBF-7743-4E38-BDCD-6F011A7B50EBQ35009521-272A8A6D-F775-44A1-B532-B81DF14A54A5Q35852614-60022355-2223-4B97-B883-A487B7DF7DC3Q35961995-956A9F3E-B7D5-46A8-85AA-BE0A9239DAE8Q36303746-CE2794D9-D547-4643-8B33-3EA603DE6C19Q36316466-2FB65DF4-BA1D-491F-9A4C-C2FD1B955F50Q36344087-01A88DF4-6EDB-4594-B2E9-22D01692BAD6Q36353657-43E29C2B-7914-44C7-A6D5-F4193C928433Q36595916-F6072C6F-82B1-495C-B812-8875975FF2B6Q37600381-8B34DAF7-1AF2-4601-BE73-401D73DF4C76Q37920916-B14DAD0C-7C6D-4534-B53E-8AA535144C41Q38038547-17129812-C0FA-4211-818D-7C0F8515B22EQ38086603-56F435B2-2DF1-46AE-8044-AC9210B09FA6Q40619709-DA30664F-D4B6-4E2A-BDEE-F3840E5BE447Q42001999-96895BD5-FA4B-46AB-BCA6-4EA59C814555Q43816378-527408B9-B22D-49EA-B494-38A8AD3BD3FEQ46361713-2B495BA0-4D49-461B-8724-CC7423F1E0E4Q46556849-3B055F03-6116-4E62-BAA9-AAB3E78E874BQ47263968-06A218FE-414F-45ED-AD71-82BB17BA799CQ50109862-71C785A7-DDD9-4F55-9B00-CAF25F7FBE68
P2860
Intestinal UGTs as potential modifiers of pharmacokinetics and biological responses to drugs and xenobiotics.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Intestinal UGTs as potential m ...... nses to drugs and xenobiotics.
@ast
Intestinal UGTs as potential m ...... nses to drugs and xenobiotics.
@en
type
label
Intestinal UGTs as potential m ...... nses to drugs and xenobiotics.
@ast
Intestinal UGTs as potential m ...... nses to drugs and xenobiotics.
@en
prefLabel
Intestinal UGTs as potential m ...... nses to drugs and xenobiotics.
@ast
Intestinal UGTs as potential m ...... nses to drugs and xenobiotics.
@en
P2860
P356
P1476
Intestinal UGTs as potential m ...... nses to drugs and xenobiotics.
@en
P2093
Joseph K Ritter
P2860
P304
P356
10.1517/17425255.3.1.93
P407
P577
2007-02-01T00:00:00Z